PRESS RELEASE published on 06/05/2025 at 14:30, 9 months 28 days ago Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome Telomir-1 treatment shows promising results in reversing aging hallmarks in a rare genetic disorder. Findings include restored gene control, extended telomere length, muscle and weight recovery, reduced oxidative stress, and 100% survival Preclinical Data Genetic Disorder Telomir-1 Age-Reversal Telomere Length
BRIEF published on 06/02/2025 at 14:35, 10 months 1 day ago Telomir Pharmaceuticals to Advance Age-Reversal Research at BIO 2025 Rare Diseases IND Submission Telomir-1 Age-Reversal Preclinical Success
BRIEF published on 06/02/2025 at 14:35, 10 months 1 day ago Telomir Pharmaceuticals fera progresser la recherche sur l'inversion du vieillissement au BIO 2025 Maladies Rares Telomir-1 Inversion Du Vieillissement Soumission IND Succès Préclinique
PRESS RELEASE published on 06/02/2025 at 14:30, 10 months 1 day ago Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform Telomir Pharmaceuticals, Inc. to meet prospective partners at BIO International Convention 2025 to accelerate IND submission for Telomir-1, preparing for human dosing in 2026 BIO International Convention IND Submission Telomir-1 Telomir Pharmaceuticals Human Dosing
BRIEF published on 05/29/2025 at 14:35, 10 months 5 days ago Telomir-1 Shows Promise in Restoring Vision in AMD Animal Model Telomir-1 Retina Regeneration AMD Model Zebrafish Study Vision Restoration
BRIEF published on 05/29/2025 at 14:35, 10 months 5 days ago Telomir-1 s'avère prometteur pour restaurer la vision dans un modèle animal de DMLA Telomir-1 Régénération De La Rétine Modèle AMD Étude Sur Le Poisson Zèbre Restauration De La Vision
PRESS RELEASE published on 05/29/2025 at 14:30, 10 months 5 days ago Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints Telomir Pharmaceuticals reports positive preclinical results for oral drug Telomir-1 in age-related macular degeneration (AMD) model, showing vision restoration, retinal regeneration, and reduced oxidative stress Preclinical Results Telomir-1 Telomir Pharmaceuticals Age-related Macular Degeneration Vision Restoration
BRIEF published on 05/15/2025 at 14:05, 10 months 19 days ago Telomir Pharmaceuticals Introduces Telomir-Ag2, Targeting Drug-Resistant Infections Antimicrobial Resistance Healthcare Market Telomir Pharmaceuticals Silver(II) Stabilization Drug-resistant Pathogens
BRIEF published on 05/15/2025 at 14:05, 10 months 19 days ago Telomir Pharmaceuticals présente Telomir-Ag2, un médicament ciblant les infections résistantes aux médicaments Résistance Aux Antimicrobiens Telomir Pharmaceuticals Stabilisation À L'argent (II) Agents Pathogènes Résistants Aux Médicaments Marché De La Santé
PRESS RELEASE published on 05/15/2025 at 14:00, 10 months 19 days ago Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity Telomir Pharmaceuticals, Inc. announces Telomir-Ag2, a novel drug candidate addressing antimicrobial resistance with broad-spectrum activity, particularly against drug-resistant pathogens Antimicrobial Resistance Drug Candidate Telomir Pharmaceuticals Inc. Telomir-Ag2 Silver(II) Complex
Published on 04/02/2026 at 22:00, 1 day 7 hours ago Star Copper Announces Closing of Charity Flow-Through Unit Private Placement
Published on 04/02/2026 at 18:32, 1 day 10 hours ago Datavault AI CEO Nathaniel Bradley to Present DataValue(R), DataScore(R), and Information Data Exchange(R) Technologies at XRP Tokyo 2026
Published on 04/02/2026 at 15:00, 1 day 14 hours ago Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Published on 04/02/2026 at 14:40, 1 day 14 hours ago Northfield Capital Completes Acquisition Of Additional Interest In Juno Corp. And Announces Issuance Of Class B Multiple Voting Shares
Published on 04/02/2026 at 14:30, 1 day 14 hours ago Worksport Announces COR(TM) Portable Energy System Is Now Fully Certified, Including Key UL and CSA Approvals, for North American Retail and Commercial Distribution
Published on 04/04/2026 at 02:05, 3 hours 22 minutes ago Blokees made its debut at 2026 Thailand Toy Expo, exhibiting multiple products
Published on 04/03/2026 at 18:00, 11 hours 27 minutes ago IEVA GROUP: IMPLEMENTATION OF A LIQUIDITY AGREEMENT WITH CREDIT INDUSTRIEL ET COMMERCIAL
Published on 04/03/2026 at 18:00, 11 hours 27 minutes ago IEVA GROUP: MISE EN OEUVRE D’UN CONTRAT DE LIQUIDITE AVEC LE CREDIT INDUSTRIEL ET COMMERCIAL
Published on 04/03/2026 at 17:45, 11 hours 42 minutes ago Atbash Launches on Chromia to Enable Verifiable, User-Controlled AI Systems
Published on 04/03/2026 at 17:40, 11 hours 47 minutes ago BROADPEAK SA: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 01.04.26.
Published on 04/03/2026 at 18:46, 10 hours 41 minutes ago Disclosure of Share Capital and Voting Rights as of March 31, 2026
Published on 04/03/2026 at 18:46, 10 hours 41 minutes ago Déclaration du nombre d’actions et droits de vote au 31 mars 2026
Published on 04/03/2026 at 18:01, 11 hours 26 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2026 at 18:00, 11 hours 27 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2026 at 18:00, 11 hours 27 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 mars 2026